Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225336 | 1.00 | ROCK2 (0.47) | ROCK2CCR2ROCK1OPRM1OPRK1 | |
| SCHEMBL4227153 | 0.94 | ACHE (0.46) | ROCK2CCR2ROCK1JAK2JAK3 | |
| SCHEMBL4227139 | 0.94 | ACHE (0.46) | ROCK2CCR2ROCK1JAK2JAK3 | |
| SCHEMBL4217867 | 0.92 | CCR2 (0.46) | ROCK2CCR2ROCK1KAT2BJAK2 | |
| SCHEMBL4217875 | 0.92 | CCR2 (0.46) | ROCK2CCR2ROCK1KAT2BJAK2 | |
| SCHEMBL4228350 | 0.92 | JAK2 (0.50) | ROCK2CCR2ROCK1KAT2BJAK2 | |
| SCHEMBL4228357 | 0.92 | JAK2 (0.50) | ROCK2CCR2ROCK1KAT2BJAK2 | |
| SCHEMBL4217621 | 0.91 | KAT2B (0.49) | ROCK2CCR2ROCK1KAT2BJAK2 | |
| SCHEMBL4217616 | 0.91 | KAT2B (0.49) | ROCK2CCR2ROCK1KAT2BJAK2 | |
| Hydrochloric Acid SCHEMBL4215447 | 0.90 | HDAC1 (0.45) | ROCK2CCR2ROCK1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | ROCK2 1607/4885CCR2 1871/4885ROCK1 1398/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | ROCK2 1991/4885CCR2 1918/4885ROCK1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.